New Tufts CSDD Study on End-to-End Site Identification Through Startup

New study assessing sponsor and CRO experience, practices and improvement areas associated with investigative site identification, feasibility, selection and study startup.

Tufts Center for the Study of Drug Development (CSDD) presents the findings of a new study among sponsors and CROs assessing the end-to-end process of finding, evaluating, selecting and activating investigative sites. Building on the 2012 ‘Startup Time And Readiness Tracking’ (START) study on site activation, this new study provides a more extensive and in-depth look at sponsor and CRO experience managing the entire process.

The study also assesses current levels of satisfaction with how various tasks are handled; cycle times associated with specific activities; perceived barriers; areas where improvement opportunities exist; and the impact of investments in technology and management models.

The webinar will discuss the implications of the results and highlight key insights for sponsors and CROs to optimize their investigative site management practices.

This webinar is applicable to:

• Sponsor and CRO roles responsible for site identification, feasibility assessment and selection
• Sponsor and CRO roles responsible for site activation
• Sponsor and CRO roles responsible for collecting and evaluating site and study metrics

Speakers

Ken Getz, Director of Sponsored Research Programs & Associate Professor, Tufts CSDD

Mr. Getz is an internationally recognized expert on R&D and clinical trial management practices and trends, the global investigative site landscape, site management and patient recruitment and retention practices, and the worldwide market for outsourcing clinical research functions. Mr. Getz’s research studies on protocol design complexity and clinical research efficiency and effectiveness, conducted over the past two decades, are considered by many in the research-based life sciences industry to be pioneering work. His 20+ years of original research benchmarking R&D management practices, global outsourcing and the investigative site landscape have contributed to industry-wide understanding of these critical markets and to improvements in management strategy and execution.

Message Presenter

Beth Harper, President, Clinical Performance Partners

Beth is the President of Clinical Performance Partners, Inc., a clinical research consulting firm specializing in enrollment and site performance management and facilitating productive sponsor-site relationships. Beth leverages her 30 years of site, SMO, CRO, Pharma, Consulting, Training and Service Provider experiences, both domestically and internationally, to identify solutions for optimizing the clinical trials process.

Message Presenter

Patricia Smith, Business Architect, goBalto

Patricia has over 20 years of experience in the health care sector, with a focus on Study Startup, including clinical trial agreement (CTA) negotiation and finalization, per subject costing development, global startup oversight and management, and global transparency compliance.

Message Presenter